PharmaSGP Holding SE
XETRA:PSG
Relative Value
The Relative Value of one PSG stock under the Base Case scenario is 35.64 EUR. Compared to the current market price of 22.8 EUR, PharmaSGP Holding SE is Undervalued by 36%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
PSG Competitors Multiples
PharmaSGP Holding SE Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
DE |
PharmaSGP Holding SE
XETRA:PSG
|
273.5m EUR | 3.1 | 20.8 | 10.6 | 15.6 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
716.9B USD | 20 | 116.8 | 57.2 | 65.1 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.4 | 45.4 | 33.2 | 36.2 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
356.2B USD | 4.2 | 9.3 | 11.4 | 14.9 | ||
US |
Merck & Co Inc
NYSE:MRK
|
321.2B USD | 5.2 | 139.3 | 33.2 | 52.6 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.4 | 140.7 | 225.7 | ||
CH |
Novartis AG
SIX:NOVN
|
180B CHF | 4.3 | 13.4 | 9.8 | 16.2 | ||
CH |
Roche Holding AG
SIX:ROG
|
174.5B CHF | 3 | 15.2 | 8.6 | 10.3 | ||
US |
Pfizer Inc
NYSE:PFE
|
158.8B USD | 2.9 | -513.9 | 12.8 | 20.3 |